Tiotropium safety in 'real-world' populations:Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology by Wise, Robert et al.
Syddansk Universitet
Tiotropium safety in 'real-world' populations
Wise, Robert; Anzueto, Antonio; Dahl, Ronald; Dusser, Daniel; Calverley, Peter MA
Published in:









Citation for pulished version (APA):
Wise, R., Anzueto, A., Dahl, R., Dusser, D., & Calverley, P. M. A. (2016). Tiotropium safety in 'real-world'
populations: Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology. British Journal of
Clinical Pharmacology, 82(2), 562–563 . DOI: 10.1111/bcp.12972
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 19. Apr. 2017
LETTER TO THE EDITOR
Tiotropium safety in ‘real-world’ populations
Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology
Correspondence Professor Robert Wise, MD, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Tel.: +1 410 550 0545;
Fax: +1 410 550 2612; E-mail: rwise@jhmi.edu
Received 13 January 2016; accepted 23 March 2016
Robert Wise1, Antonio Anzueto2, Ronald Dahl3, Daniel Dusser4 and Peter Calverley5
1Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2University of Texas and South Texas Veterans Health Care System, San Antonio,
TX, USA, 3Odense University Hospital, Odense C, Denmark, 4Service de Pneumologie Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne
Paris Cité, Paris, France and 5Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
We read with interest the publication of Schmiedl et al. [1]
describing the characteristics of patients treated with
tiotropium HandiHaler® or Respimat® in the Tiotropium
Safety and Performance in Respimat (TIOSPIR®) study com-
pared with their ‘real-world’ database [2]. The authors noted
that patients starting either treatment had similar character-
istics but suggest that we may have included a selected popu-
lation with chronic obstructive pulmonary disease (COPD),
who might react differently to treatment (and be at lower risk
of cardiac adverse effects) than a ‘real-world’ population.
The baseline characteristics of the patients with COPD
enrolled in placebo-controlled tiotropium studies using
HandiHaler® or Respimat® were recently compared with those
from a range of epidemiological studies. Patients included in
tiotropium studies were found to be widely representative of
the overall COPD population [3]. While ‘real-world’ observa-
tional studies may be useful in generating relevant clinical
questions, randomized controlled trials, such as TIOSPIR®, use
robust methodologies designed and powered to answer these.
As Schmiedl et al. [1] note, one of the main reasons for their
‘real-world’ patients notmeeting the inclusion/exclusion criteria
of TIOSPIR® was a diagnosis of asthma. Indeed, a concomitant
diagnosis of asthma was an exclusion criterion in most studies
of tiotropium in COPD. On the other hand, tiotropium was in-
vestigated in a large clinical programme of patients with asthma
(including severe asthma, excluding COPD); a higher risk of
adverse cardiac effects in these patients was not identiﬁed [4].
Another criterion for exclusion from TIOSPIR® was milder
COPD [forced expiratory volume in 1 s (FEV1)>70% predicted].
While Schmiedl et al. [1] were right to highlight differences in their
‘real-world’ population from those meeting more stringent
criteria in clinical trials, there is no reason to believe that pa-
tients with milder disease would be at any additional speciﬁc
risk for adverse cardiac effects with tiotropium treatment be-
yond the assessments performed in TIOSPIR®. On the contrary,
as TIOSPIR® was a safety study, and therefore focused on
patients with more severe respiratory disease, it would be
expected that any safety signal would be more evident than in
an overall ‘real-world’ population, which was not the case.
Owing to the speciﬁc exclusion criteria of tiotropium trials,
some differences in characteristics compared with patients in
clinical practice do remain. For example, TIOSPIR® [2] [and also
the 4-year Understanding Potential Long-term Impacts on
Function with Tiotropium (UPLIFT®) trial of tiotropium
HandiHaler®] [5] excluded patients with moderate-to-severe
renal impairment. However, a pooled analysis of 22 blinded,
placebo-controlled studies of tiotropium HandiHaler® and
Respimat® in which baseline serum creatinine was collected
did not indicate an increased risk for all-cause or cardiac mortal-
ity, or serious adverse events, in patients with COPD and
existing mild-to-moderate renal impairment [3, 6–8].
Patients with recent severe cardiac events [myocardial infarc-
tion within ≤6 months, unstable/life-threatening arrhythmia re-
quiring intervention or change in treatment, or hospitalization
with severe (New York Heart Association class III/IV) cardiac fail-
ure within ≤1 year] were also excluded from tiotropium trials
[9]. To investigate the safety of tiotropium in patients with a re-
cent history of cardiac events, patients in UPLIFT® and TIOSPIR®
were followed up for mortality and cardiac adverse events
occurring after an initial on-treatment cardiac event, while con-
tinuing on therapy. Neither the results for tiotropium
HandiHaler® vs. placebo (UPLIFT®) [10], nor for tiotropium
Respimat® vs. HandiHaler® (TIOSPIR®) [11], indicated a speciﬁc risk
for subsequent mortality or cardiac events in this high-risk group.
Another possible confounder could be the selection of pa-
tients with high tolerability for anticholinergic agents (i.e.
pretreated with this class of drug). While this could explain the
variation in results between TIOSPIR® and some epidemiological
studies, the analysis of a large group of patients from TIOSPIR®
who were anticholinergic-naïve at baseline did not indicate any
differential effects vs. the total study population, or between
the tiotropium HandiHaler® and Respimat® groups [12].
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To conclude, while it is true that certain groups of patients
may be under-represented in individual studies of tiotropium,
the very large clinical trial database [9] (including long-term
studies of up to 4 years’ duration) allows for comprehensive sub-
group analyses of patients potentially at risk and, in our opin-
ion, supports the safety of tiotropium in these patients.
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